Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biweekly cabazitaxel in docetaxel-pretreated castration-resistant prostate cancer
2012-000996-17Phase 2Active
- Sponsor
- Azienda Ospedaliero-Universitaria Policlinico Umberto I
- Start
- Aug 2012
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabazitaxel in prostate cancer (PCa), sponsored by Azienda Ospedaliero-Universitaria Policlinico Umberto I. Primary endpoint: Incidence of grade 3 or 4 neutropenia. Started Aug 2012; status: active.
02
Drugs
cabazitaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2012-000996-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000996-17.